A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer’s Disease

(E-pub Ahead of Print)

Author(s): Jan Korabecny , Katarina Spilovska, Eva Mezeiova , Ondrej Benek , Radomir Juza , Daniel Kaping , Ondrej Soukup*.

Journal Name: Current Medicinal Chemistry

Become EABM
Become Reviewer


Alzheimer’s disease (AD) is a multifactorial progressive neurodegenerative disorder characterized by memory loss, disorientation, and gradual deterioration of intellectual capacity. Its etiology has not been elucidated yet. To date, only one therapeutic approach has been approved for the treatment of AD. The pharmacotherapy of AD has relied on noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist - memantine, and acetylcholinesterase (AChE) inhibitors (AChEIs) - tacrine, donepezil, rivastigmine and galantamine. Donepezil was able to ameliorate the symptoms related to AD mainly via AChE, but also through reduction of β-amyloid burden. This review presents the overview of donepezilrelated compounds as potential anti-AD drugs developed on the basis of cholinergic hypothesis to act as solely AChE and butyrylcholinesterase (BChE) inhibitors.

Keywords: Alzheimer’s disease, acetylcholinesterase, butyrylcholinesterase, donepezil, inhibitor, treatment.

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/0929867325666180517094023
Price: $95

Article Metrics

PDF: 18